Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Venetoclax. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 known ✓ | P10415 | 20/20 | 1.00 |
| ▸ | BCL2L1 | Q07817 | 4/20 | 1.00 |
| ▸ | MCL1 | Q07820 | 2/20 | 1.00 |
| ▸ | BCL2L2 | Q92843 | 2/20 | 1.00 |
| ▸ | NSD2 | O96028 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | BID | P55957 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
| ▸ | ASPH | Q12797 | 1/20 | 1.00 |
| ▸ | BAD | Q92934 | 1/20 | 1.00 |
| ▸ | NSD1 | Q96L73 | 1/20 | 1.00 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 1.00 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.89 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Venetoclax SCHEMBL29801595 | 1.00 | BCL2 (1.00) | BCL2BCL2L1MCL1BCL2L2NSD2 | |
| Venetoclax SCHEMBL29390802 | 1.00 | BCL2 (1.00) | BCL2BCL2L1MCL1BCL2L2NSD2 | |
| Venetoclax SCHEMBL29353714 | 1.00 | BCL2 (1.00) | BCL2BCL2L1MCL1BCL2L2NSD2 | |
| Venetoclax SCHEMBL523816 | 1.00 | BCL2 (1.00) | BCL2BCL2L1MCL1BCL2L2NSD2 | |
| Venetoclax SCHEMBL19278845 | 0.99 | BCL2 (0.99) | BCL2BCL2L1MCL1BCL2L2NSD2 | |
| Venetoclax SCHEMBL19278892 | 0.99 | BCL2 (0.98) | BCL2BCL2L1MCL1BCL2L2NSD2 | |
| Venetoclax SCHEMBL19278891 | 0.99 | BCL2 (0.98) | BCL2BCL2L1MCL1BCL2L2NSD2 | |
| SCHEMBL16038769 | 0.98 | BCL2 (0.96) | BCL2BCL2L1MCL1BCL2L2NSD2 | |
| SCHEMBL16038376 | 0.98 | BCL2 (0.96) | BCL2BCL2L1MCL1BCL2L2NSD2 | |
| SCHEMBL1699816 | 0.98 | BCL2 (0.96) | BCL2BCL2L1MCL1BCL2L2NSD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 189 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250268985-A1 | BCL2 INHIBITOR AND PEPTIDE COMBINATION THERAPY FOR TREATING PROLIFERATIVE DISEASES | IMMUNE SYSTEM KEY LTD. (IL) | 2025-08-28 | — | — | US | claimed |
| US-20250161351-A1 | CANCER TREATMENT BY ARSENIC TRIOXIDE COMBINATION THERAPY | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2025-05-22 | — | — | US | claimed |
| WO-2025097150-A1 | BCL-2 INHIBITION TO AMPLIFY CHIMERIC ANTIGEN RECEPTOR THERAPY | THE UNIVERSITY OF CHICAGO (US) | 2025-05-08 | — | — | WO | claimed |
| EP-4536250-A1 | CANCER TREATMENT BY ARSENIC TRIOXIDE COMBINATION THERAPY | Deutsches Krebsforschungszentrum (DE) | 2025-04-16 | — | — | EP | claimed |
| EP-4507709-A1 | BCL2 INHIBITOR AND PEPTIDE COMBINATION THERAPY FOR TREATING PROLIFERATIVE DISEASES | Immune System Key Ltd. (IL) | 2025-02-19 | — | — | EP | claimed |
| CN-119300853-A | Bcl2 inhibitors and peptide combination therapies for the treatment of proliferative diseases | 免疫系统密钥有限公司 | 2025-01-10 | — | — | CN | claimed |
| EP-4346834-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE | Janssen Pharmaceutica NV (BE) | 2024-04-10 | — | — | EP | claimed |
| WO-2023237710-A1 | CANCER TREATMENT BY ARSENIC TRIOXIDE COMBINATION THERAPY | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2023-12-14 | — | — | WO | claimed |
| WO-2023199313-A1 | BCL2 INHIBITOR AND PEPTIDE COMBINATION THERAPY FOR TREATING PROLIFERATIVE DISEASES | IMMUNE SYSTEM KEY LTD. (IL) | 2023-10-19 | — | — | WO | claimed |
| WO-2023161940-A1 | APOPTOSIS RELATED PROTEIN IN THE TGF-BETA SIGNALING PATHWAY (ARTS) MIMETIC COMPOUNDS, COMPOSITIONS, METHODS AND USES THEREOF IN INDUCTION OF APOPTOSIS | CARMEL-HAIFA UNIVERSITY ECONOMIC CORPORATION LTD. (IL) | 2023-08-31 | — | — | WO | claimed |
| EP-4218731-A2 | MELT-EXTRUDED SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | AbbVie Ireland Unlimited Company (IE) | 2023-08-02 | — | — | EP | claimed |
| EP-3370775-B1 | COMBINATION OF BCL-2 INHIBITOR AND MEK INHIBITOR FOR THE TREATMENT OF CANCER | GENENTECH INC (US) | 2023-04-19 | — | — | EP | claimed |
| WO-2022254371-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2022-12-08 | — | — | WO | claimed |
| US-20220306625-A1 | COMPOUNDS HAVING ((3-NITROPHENYL)SULFONYL)ACETAMIDE AS BCL-2 INHIBITORS | EIL THERAPEUTICS INC (US) | 2022-09-29 | — | — | US | claimed |
| WO-2026101931-A1 | METHODS OF TREATING MYELODYSPLASTIC SYNDROME | GERON CORPORATION (US) | 2026-05-15 | — | — | WO | disclosed |
| EP-4735452-A2 | HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF KRAS PROTEIN | Merck Patent GmbH (DE) | 2026-05-06 | — | — | EP | disclosed |
| US-12605387-B2 | Treatment of cancers using PI3 kinase isoform modulators | SECURA BIO, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| WO-2022032132-A1 | ADVANTAGEOUS THERAPIES FOR DISORDERS MEDIATED BY IKAROS OR AIOLOS | C4 THERAPEUTICS, INC. (US) | 2022-02-10 | — | — | WO | disclosed |
| WO-2022019920-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | VERASTEM, INC. (US) | 2022-01-27 | — | — | WO | disclosed |
| EP-3941462-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Achillion Pharmaceuticals, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220306625-A1 | COMPOUNDS HAVING ((3-NITROPHENYL)SULFONYL)ACETAMIDE AS BCL-2 INHIBITORS | BCL2, BCL2A1, BCL2L1 | BCL2 1/4885BCL2L1 3/4885MCL1 18/4885 |
| US-12605387-B2 | Treatment of cancers using PI3 kinase isoform modulators | PIK3R5, PIK3R4, PIK3CD | BCL2 797/4885BCL2L1 1410/4885MCL1 237/4885 |
| US-20250268985-A1 | BCL2 INHIBITOR AND PEPTIDE COMBINATION THERAPY FOR TREATING PROLIFERATIVE DISEASES | BCL2, BCL2L13, BCL2L1 | BCL2 1/4885BCL2L1 3/4885MCL1 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.